People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nivagen Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $31.0M | $52.9M | 2023 |
Michael C. Kulper at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael C. Kulper on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jaswinder Matharu | 1 | 2 |
| Dasaradhi C. Lakkaraju | 1 | 1 |
| Gopal C. Patel | 1 | 1 |
| Jwalant Shukla | 1 | 1 |
| Rob C. Hart | 1 | 1 |
| Ashish C. Sevak | 1 | 1 |
| Praneel C. Deo | 1 | 1 |
| Ashish Sevak | 1 | 1 |
| Bikramjit Singh | 1 | 1 |
| Sharad Dadbhawala | 1 | 1 |
| Bikram Singh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.